Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Asset disposition
Inv. presentation
KINETA, INC. (PTI) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/11/2023 8-K Investor presentation
Docs: "0.5 0.4 0.1 0.3 0.2 0"
06/09/2023 8-K Investor presentation
Docs: "0.5 0.4 0.1 0.3 0.2 0"
03/31/2023 8-K Investor presentation
Docs: "Kineta, Inc. Corporate Presentation, dated April 2023"
01/05/2023 8-K Investor presentation
Docs: "Kineta, Inc. Corporate Presentation, dated January 2023",
"Kineta, Inc. Corporate Presentation, dated January 2023"
07/20/2022 8-K Quarterly results
11/10/2021 8-K Investor presentation
Docs: "Yumanity Therapeutics, Inc. corporate presentation, dated November 2021",
"Yumanity Therapeutics Announces Positive Top-Line Results of Phase 1b Clinical Trial for YTX-7739 in Patients with Parkinson's Disease; Company Plans to Advance Program to Phase 2"
06/16/2021 8-K Quarterly results
05/17/2021 8-K Quarterly results
01/11/2021 8-K Quarterly results
12/17/2019 8-K Investor presentation
Docs: "Proteostasis Therapeutics Announces Positive Phase 2 Topline Results from Proprietary CFTR Modulator Combinations in F508del Homozygous Cystic Fibrosis Patients",
"Presentation slides, filed herewith"
12/04/2019 8-K Investor presentation
Docs: "Corporate Presentation, furnished herewith",
"Corporate Presentation, furnished herewith"
11/01/2019 8-K Quarterly results
10/03/2019 8-K Quarterly results
08/05/2019 8-K Quarterly results
05/13/2019 8-K/A Investor presentation
Docs: "Corporate presentation, furnished herewith"
05/13/2019 8-K Investor presentation
Docs: "Corporate presentation, furnished herewith",
"Corporate presentation, furnished herewith"
03/25/2019 8-K Investor presentation
Docs: "Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communications pursuant to Rule 13e-4 under the Exchange Act ) Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934 . Emerging growth company ☒ If an emerging growth company, indicate by check mark if the registrant has elected ...",
"Proteostasis Therapeutics Announces Broad New Dataset from Proprietary Combination and Add-On CFTR Modulator Studies in Cystic Fibrosis Patients",
"Presentation slides, filed herewith"
02/27/2019 8-K Quarterly results
01/07/2019 8-K Investor presentation
Docs: "Presentation slides furnished herewith",
"Presentation slides furnished herewith"
11/28/2018 8-K Investor presentation
Docs: "Presentation slides furnished herewith",
"Presentation slides furnished herewith"
10/17/2018 8-K Quarterly results
10/03/2018 8-K Investor presentation
Docs: "Presentation slides furnished herewith",
"Presentation slides furnished herewith"
07/26/2018 8-K Investor presentation
Docs: "Presentation slides furnished herewith",
"Presentation slides furnished herewith"
06/06/2018 8-K Investor presentation
Docs: "FORM 8-K",
"Proteostasis Announces Positive Data from Ongoing Phase 1study of PTI-801 in Cystic Fibrosis Patients on Background Orkambi ® Therapy",
"Presentation slides, filed herewith"
03/14/2018 8-K Investor presentation
Docs: "Proteostasis Therapeutics, Inc. presentation"
01/08/2018 8-K Investor presentation
Docs: "Not Applicable Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communications pursuant to Rule 13e-4 under the Exchange Act ) Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934 . Emerging growth company ☒ If an emerging growth company, indicate by check mark if the registra...",
"Proteostasis' Proprietary Triple Combination Therapy Study Protocol Receives Endorsement and High Strategic Fit Score from the Largest Cystic Fibrosis Patient Advocacy Groups in the U.S. and Europe",
"Presentation slides, furnished herewith"
12/12/2017 8-K Investor presentation
Docs: "Presentation slides, filed herewith",
"Proteostasis Therapeutics Announces Positive Clinical Results from Studies of PTI-428, PTI-801 and PTI-808 in Healthy Volunteers and Patients with Cystic Fibrosis",
"Presentation slides, filed herewith"
09/25/2017 8-K Quarterly results
06/08/2017 8-K Form 8-K - Current report
03/30/2017 8-K Form 8-K - Current report
01/09/2017 8-K Form 8-K - Current report
12/09/2016 8-K Form 8-K - Current report
10/27/2016 8-K Form 8-K - Current report
08/15/2016 8-K Form 8-K - Current report

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy